Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.

Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Corcept TherapeuticsUpdated: Jun 30, 2026Locations: 4
Eligibility criteria

Signed and dated institutional review board (IRB)/ independent ethics committee... [+7]

Grade ≥ 3 [+18]

Read more
Status: Recruiting

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).

Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Corcept TherapeuticsUpdated: Jun 17, 2026Locations: 14
Eligibility criteria

Signed and dated informed consent form prior to screening procedures [+13]

Any major surgery within 4 weeks prior to enrollment [+15]

Read more
Status: Recruiting

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

Participants needed: 279
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Corcept TherapeuticsUpdated: Jun 16, 2026Locations: 35
Eligibility criteria

Male and female patients ≥18 years of age with sporadic or familial ALS. In Part... [+3]

History of a clinically significant non-ALS neurologic disorder [+10]

Read more
Status: Recruiting

Evaluating the Pharmacokinetics and Safety of Miricorilant

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Participants needed: 15
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Corcept TherapeuticsUpdated: May 26, 2026Locations: 1
Eligibility criteria

Nonalcoholic fatty liver disease (NAFLD) activity score (NAS) ≥ 3 with at least... [+8]

Women who are pregnant, planning to become pregnant, or are lactating. [+9]

Read more
Status: Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Participants needed: 270
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Corcept TherapeuticsUpdated: Apr 14, 2026Locations: 49
Eligibility criteria

Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tub... [+17]

Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel [+28]

Read more
Status: Recruiting

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Participants needed: 8
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Corcept TherapeuticsUpdated: Feb 11, 2026Locations: 1
Eligibility criteria

NAFLD Activity Score (NAS) ≥ 4 (with at least 1 point in each subcomponent of st... [+4]

Participation in another clinical trial for MASH or weight loss (e.g., GLP-1 rec... [+11]

Read more